|
Post by brentie on Jul 2, 2014 11:26:12 GMT -5
|
|
|
Post by babaoriley on Jul 2, 2014 23:40:03 GMT -5
|
|
|
Post by babaoriley on Jul 2, 2014 23:40:57 GMT -5
|
|
|
Post by babaoriley on Jul 3, 2014 9:47:00 GMT -5
|
|
|
Post by mannmade on Jul 3, 2014 9:57:52 GMT -5
Good stuff Baba... Thx!
|
|
|
Post by savzak on Jul 4, 2014 18:00:43 GMT -5
|
|
|
Post by thekindaguyiyam on Jul 6, 2014 23:37:23 GMT -5
|
|
|
Post by garrett on Jul 7, 2014 6:47:30 GMT -5
|
|
|
Post by savzak on Jul 7, 2014 10:07:56 GMT -5
From DiaTribe:
diatribe.org/issues/65/new-now-next
FDA Approves MannKind’s Rapid-Acting Inhaled Insulin, Afrezza, for type 1 and type 2 diabetes
MannKind's AfrezzaOn June 27, the FDA approved MannKind’s Afrezza for type 1 and type 2 diabetes, a new rapid-acting inhaled insulin. We’ve been following this story for years in diaTribe, and the approval marks a major win for another mealtime insulin option. There is no firm launch timeline yet, though in the past, the company expected to launch Afrezza within six months of FDA approval. MannKind has also previously stated that Afrezza would be priced roughly comparably to current rapid-acting insulins (Humalog, Novolog, and Apidra); if this is the case, we are optimistic about reimbursement for type 2 patients in particular. We think most type 1s would prefer to use it as a “supplement” to their current mealtime insulin rather than a substitute so we imagine reimbursement will be more challenging initially for type 1s.
Afrezza will come packaged as a powder that is administered with a small inhaler – based on videos and pictures we’ve seen, the device fits in the palm of the hand and is fairly unobtrusive and easy to use – you can see a video on MannKind’s website here. Based on studies, we understand that Afrezza is a very fast insulin that peaks in the blood stream within 12 to 15 minutes, much faster than currently available rapid-acting insulins that take around 50 minutes to peak.
The inhaled insulin has been approved in two dosing options – a cartridge equivalent to four units of injected rapid-acting insulin, and another equivalent to eight units. This means that patients will only be able to take Afrezza in multiples of four units, which could make it challenging to use in type 1 diabetes and for those who are very insulin sensitive. As we noted in our coverage of the phase 3 trials of Afrezza, patients with type 1 diabetes saw significant benefits to taking Afrezza such as less hypoglycemia (moderate and severe) and less weight gain compared to Novolog (insulin aspart). In type 2 diabetes, there is much less concern over the dosing, and the convenience of an inhaled, needle free insulin should be attractive to many patients.
Four additional clinical trials, post-approval, are required for Afrezza, including a long-term study to determine its cardiovascular and lung safety. People with type 1 diabetes must use Afrezza with long-acting insulin, and the FDA does not recommend Afrezza for people who smoke or who have prior lung conditions.
We believe patients and healthcare providers played a role in this approval - we applaud it as it means more treatment options for patients, which should help improve adherence to insulin and which may well bring more people with diabetes on to insulin - with nearly 45% of patients not at their glycemic targets in the US alone and only 29% on insulin (of any kind!) we believe more patients considering insulin would be a benefit. We salute with special gusto the legendary entrepreneur the CEO of MannKind, 89-year-old Mr. Al Mann, who advocated for years for Afrezza’s approval (its first two attempts at FDA approval both resulted in long delays). We look forward to hearing real-world patient use of the product – we’ll certainly be testing it out in diaTribe. For more background on Afrezza, please read our past letter from the editor, our new now next on the drug’s FDA advisory committee, and our coverage of the phase 3 trial results in type 1 and type 2 diabetes. -AJW/AB/KC
|
|
|
Post by savzak on Jul 7, 2014 10:31:34 GMT -5
This is a Chicago radio station. Start listening around the 3 minute mark. I'm not sure if this was broadcast this morning or last week.
wgnradio.com/2014/07/07/dr-kevin-most-nasal-insulin-and-the-heroin-epidemic/
"Could be a game changer I think for a lot of people in their lives...works like the pancreas..."
This Doc is explaining the benefits of Afrezza correctly from the 3:00 minute mark to the 6:00 minute mark.
Then at 13:30 mark he answers a follow up question from a listener about the application to both Type 1's and Type 2's.
|
|
|
Post by Chris on Jul 7, 2014 13:49:25 GMT -5
I have a source in Novo, they are hiring for another product...
|
|
|
Post by mannmade on Jul 7, 2014 13:52:11 GMT -5
Chris i tend to think you are right as unless they are the only ones in the discussion why hire in advance of a closed deal? Most NBA teams have same issue... w respect to King James and Melo... And notice no one is doing anything until those deals are done...
|
|
|
Post by otherottawaguy on Jul 7, 2014 15:10:37 GMT -5
I have a source in Novo, they are hiring for another product... Chris et al:
Not sure if I mentioned this here before, but when Mannkind dropped out of the Diabetes show last month, it was Novo that expanded into their reserved spot. Novo spot was adjacent and they just expanded their footprint.
You would have had to be looking at the tentative floor plan prior to Mannkind dropping out and then at the actual plan to have caught this.
OOg
|
|
|
Post by Chris on Jul 7, 2014 15:21:12 GMT -5
Mann: I hope Melo signs with the LA Lakers. Rumor states Love, Melo and Kobe were all playing a pick-up game at UCLA together.
Savak: thanks for that awesome broadcast clip, the http seems to have a date of 7/7/2014 so I'm assuming it aired this morning. When I worked as a radio DJ in college we recorded our shows and uploaded them same day with the date format like your link shows.
OOG: Interesting, thanks for sharing but perhaps when MNKD pulled out, the host of the conference notified companies of an available spot to sell as not to leave it vacant? Since most conferences have specific locations for certain companies, maybe MNKD and NVO were in the diabetes section and once MNKD left, NVO capitalized on the opportunity especially since it was within proximity to an already existing stand? Just throwing guesses and a new persepective as not to read into the tea leaves to heavily.
|
|
|
Post by otherottawaguy on Jul 7, 2014 15:25:31 GMT -5
Wasn't trying to say its Novo for sure, just wanted to put my observation out there. Might be a thin thin thread in this tapestry that we call Mannkind.
Side note: Is anyone else tracking the conversation by the new poster from the UK on YMB that the deal is done? Says Lily and Merck are out and that the company name begins with "No"
Sounds like fluff, but interesting non the less.
OOGG
|
|